Home
Resources
Publications
Viro-immunological Outcomes After 13-valent Pneumococcal Vaccination in HIV-1-infected Individuals on Stable Virological Suppression

Viro-immunological Outcomes After 13-valent Pneumococcal Vaccination in HIV-1-infected Individuals on Stable Virological Suppression

Raffaele Dell'Acqua, Laura Galli, Andrea Poli, Andrea Mastrangelo, Monica Guffanti, Patrizia Tadini, Daniela Zandona, Anna Danise, Nicola Gianotti, Adriano Lazzarin, Antonella Castagna, Silvia Nozza

AIDS. 2019 Nov 1;33(13):1987-1994.

PMID: 31306174

Abstract:

Background:
Very limited data are available on the immunovirological outcomes after 13-valent pneumococcal conjugate vaccine (PCV13) in antiretroviral therapy (ART)-treated patients. The aim of this study was to assess the immune-virological outcomes in HIV-1-infected ART-treated patients on stable virological suppression who underwent pneumococcal conjugate vaccination.
Methods:
Retrospective, cohort study on ART-treated HIV-1-infected individuals, age at least 18 years, with three consecutive determinations of HIV-RNA less than 50 copies/ml before the administration of PCV13 (baseline) at San Raffaele Hospital and with at least two HIV-RNA values after vaccination.
Results:
Overall 1197 patients underwent PCV13 vaccination. During 6-month of follow-up (594 person-years of follow-up, PYFU), 12 confirmed virological failure and 35 viral blips were observed; the overall incidence rate of confirmed virological failure was 2.02 (95% confidence interval: 0.88-3.16) per 100-PYFU and the incidence rate of viral blips was 5.89 (95% confidence interval: 3.94-7.84) per 100-PYFU. Median CD4 cell count change from baseline at 6 months was +10 cells/μl (interquartile range -67, +111; P = 0.0002). Median change in CD4/CD8 ratio was +0.02 (interquartile range -0.06, +0.11; P < 0.001).
Conclusion:
Viral blips and confirmed virological failures were rarely observed in patients on stable virological suppression in the first 6 months following vaccination with PCV13. In addition, no decrease of CD4 cell count and CD4/CD8 ratio was recorded.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
IAR424669	Ovalbumin-Atto 594 conjugate			Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: